Ivan Kairatov is a seasoned biopharma expert, having dedicated numerous years to the advancement of innovation and technology in the field. He has substantial experience in research and development, making him a prominent figure to discuss the outcomes and implications of new clinical trials, such
As a promising new frontier in cancer treatment, histotripsy represents a significant advancement in non-invasive medical procedures aimed at eliminating tumors. The technique utilizes bubbles generated via precise ultrasound waves to target and destroy specific cancer cells. Notably, histotripsy
The collaborative research effort between UC Berkeley and UC San Francisco introduces a groundbreaking speech neuroprosthesis designed to restore naturalistic speech for individuals experiencing severe paralysis. This pioneering technology addresses the critical issue of latency, allowing brain
Innovation thrives at the intersection of regulatory flexibility and robust oversight, especially within the dynamic field of first-in-class drugs. Today, we delve into this critical topic with Ivan Kairatov, a seasoned biopharma expert with extensive experience in research and development. With a
The recent results from the pivotal Phase 3 ROSELLA trial mark a significant development in the battle against platinum-resistant ovarian cancer. Corcept Therapeutics announced that the trial successfully demonstrated the efficacy of combining relacorilant with nab-paclitaxel chemotherapy,
Advancements in artificial intelligence (AI) have facilitated significant progress in heart attack diagnosis, specifically through an AI model trained to identify blocked coronary arteries using electrocardiogram (ECG) readings. This groundbreaking technology has been found to outperform human
